Sagent Pharmaceuticals has introduced Flumazenil Injection, USP, available in two latex-free vials featuring the PreventIV Measures packaging and labeling.
The benzodiazepine antagonist is indicated for the complete or partial reversal of the sedative effects of benzodiazepines.
Flumazenil injection is used in cases where general anesthesia has been induced with benzodiazepines, where sedation has been produced for diagnostic and therapeutic procedures with benzodiazepines, and to manage benzodiazepine overdose.
Flumazenil Injection, USP, has US sales of $5.6m for the year ending September 2012, according to IMS data.
Sagent is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
